KPV
KPV is a synthetic tripeptide (Lys-Pro-Val) derived from alpha-MSH, studied for gut and systemic inflammation; research protocols typically use 200 mcg daily subcutaneously.
Best for
KPV has been studied primarily for gut and systemic inflammation, including animal models of inflammatory bowel disease (colitis), as well as contact dermatitis and other inflammatory conditions.
What to expect
Research has not established a defined human time-to-effect; preclinical inflammation models typically report changes over days of repeated administration rather than acute single-dose effects.
Pairs with
In research and protocol discussions KPV is commonly grouped with gut-repair and recovery peptides such as BPC-157 and TB-500, though combination use has not been formally validated in controlled human studies.
In research settings KPV has been administered orally and via injectable subcutaneous routes, with low (often microgram-to-low-milligram) daily amounts described in non-clinical work; no standardized human dosing is established.
These figures are research-community reference points; no controlled human dose has been established.
- How often
- Daily
- Route
- Subcutaneous
- Vial & water
- 10 mg vial in 3 mL = 3.33 mg/mL · 200 mcg = 6 units on a U-100 syringe
- Cycle
- Continuous
The same numbers the goodtides app and the Dose Calc use — a research reference, not a prescription. Responses are individual; research protocols start at the low end.
KPV is a synthetic tripeptide (Lys-Pro-Val) corresponding to the C-terminal sequence (residues 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH), the body's endogenous melanocortin peptide. Research has characterized KPV as retaining much of alpha-MSH's anti-inflammatory signaling while lacking the pigment-stimulating activity of the full hormone.
KPV is not FDA-approved; it is used as a research compound and is not an approved drug for any indication.
Mechanistic studies report that KPV is taken up into intestinal epithelial and immune cells via the di/tripeptide transporter PepT1 (which is upregulated in the inflamed colon), where nanomolar concentrations have been shown to inhibit activation of the NF-kappaB and MAP-kinase inflammatory signaling pathways and to reduce secretion of pro-inflammatory cytokines such as TNF-alpha and IL-6. In rodent models, oral KPV reduced the severity of DSS- and TNBS-induced colitis.
- Half-life
- ~30 min
- Peak
- ~30 min post-SC
- Absorption
- SC or oral (gut-localized)
- Bioavailability
- SC ~80%; oral lower but locally active
References3
- Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Gastroenterology) (mouse model)
- Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease (Inflamm Bowel Dis) (murine model)
- Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs (Ann Rheum Dis)
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.